BlackRock Inc. Buys Shares of 7,539,602 Omnicell, Inc. $OMCL

Key Points

• BlackRock acquired 7.54 million Omnicell shares during the second quarter, worth approximately $313 million, giving it a 16.58% stake. Institutional investors collectively own 97.70% of OMCL.
• Omnicell reported quarterly earnings of $0.94 per share, beating estimates by $0.47, while revenue rose 7.4% year over year to $312.21 million. The company guided for third-quarter 2026 EPS of $0.35–$0.43 and full-year EPS of $2.15–$2.30.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $57.86, although targets and ratings vary, including a recent “strong sell” call from Zacks Research.

BlackRock Inc. bought a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,539,602 shares of the company's stock, valued at approximately $313,044,000. BlackRock Inc. owned approximately 16.58% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. acquired a new position in shares of Omnicell in the 2nd quarter valued at $26,000. Versant Capital Management Inc grew its stake in Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock valued at $44,000 after acquiring an additional 294 shares during the period. Clearstead Advisors LLC grew its position in shares of Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in Omnicell during the 4th quarter worth approximately $58,000. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock worth $61,000 after acquiring an additional 1,264 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Omnicell Stock Up 0.7%

NASDAQ:OMCL opened at $33.45 on Thursday. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 39.82, a price-to-earnings-growth ratio of 0.83 and a beta of 0.98. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13. The stock's fifty day moving average is $40.04 and its two-hundred day moving average is $39.40.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. The firm had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on OMCL shares. KeyCorp reaffirmed an "overweight" rating on shares of Omnicell in a research note on Monday. Weiss Ratings upgraded shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 18th. Piper Sandler restated an "overweight" rating and set a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Craig Hallum restated a "buy" rating and issued a $55.00 price target on shares of Omnicell in a research report on Wednesday, April 29th. Finally, Zacks Research cut Omnicell from a "hold" rating to a "strong sell" rating in a report on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $57.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source